Cancer Detection Biotech YD Bio Goes Public: $11.5M SPAC Deal Powers DNA Methylation Tech

YD Bio Limited (NASDAQ: YDES) has successfully completed its business combination with Breeze Holdings Acquisition Corp and will begin trading on the Nasdaq Global Market on August 29, 2025. The company secured over $11.5 million in funding through a PIPE offering and trust proceeds.

Led by Chairman Dr. Ethan Shen, YD Bio focuses on three core areas: DNA methylation-based cancer detection technology, stem cell and exosome-based ophthalmology therapies, and clinical trial support services. Key developments include a pancreatic cancer screening test available as an LDT, an upcoming breast cancer monitoring test, and planned trials for exosome-based ophthalmic treatments in 2027.

https://www.stocktitan.net/news/YDES/yd-bio-limited-announces-closing-of-business-combination-and-listing-8ljcqne4wcp2.html